Cargando…

Hyperinflammation in COVID-19 Obese Patients Treated With Tocilizumab: A Successful Case Series

The cytokine storm syndrome has been suggested as a mechanism in the pathophysiology of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2; COVID-19 [coronavirus disease 2019]) infection. Drugs such as tocilizumab, an interleukin-6 antagonist, have shown good results in other scenarios of h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beltrão, Beatriz Amorim, Teixeira, Rafael Cabral, Porto, Diego Bastos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326622/ https://www.ncbi.nlm.nih.gov/pubmed/34334015 http://dx.doi.org/10.1177/23247096211037442

Ejemplares similares

2648. Taming the Cytokine Storm: Baricitinib versus Tocilizumab for COVID-19 Hyperinflammation
por: Radziszewski, Skyler, et al.
Publicado: (2023)

Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation
por: Potere, Nicola, et al.
Publicado: (2020)

COVID-19 Induced Cardiomyopathy Successfully Treated with Tocilizumab
por: Schreiber, Ariyon, et al.
Publicado: (2022)

COVID-19 INDUCED CARDIOMYOPATHY SUCCESSFULLY TREATED WITH TOCILIZUMAB
por: Fakhra, Sadaf, et al.
Publicado: (2022)

Immunopathology of Hyperinflammation in COVID-19
por: Gustine, Joshua N., et al.
Publicado: (2021)

Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a case series
por: Clark, Kristina E N, et al.
Publicado: (2020)

Management of hyperinflammation in COVID-19 patients
por: Suberviola, Borja, et al.
Publicado: (2022)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

COVID-19 Hyperinflammation: What about Neutrophils?
por: Didangelos, Athanasios
Publicado: (2020)

Frontal encephalopathy related to hyperinflammation in COVID-19
por: Cani, Ilaria, et al.
Publicado: (2020)

Delving beneath the surface of hyperinflammation in COVID-19
por: Reddy, Kiran, et al.
Publicado: (2020)

Hyperinflammation with COVID-19: The key to patient deterioration?()()
por: Haigh, Kathryn, et al.
Publicado: (2020)

Post-COVID-19 arthritis: is it hyperinflammation or autoimmunity?
por: Taha, Sara Ibrahim, et al.
Publicado: (2022)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: comment
por: Yurttutan, Sadık, et al.
Publicado: (2021)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Successful treatment of severe COVID-19 pneumonia with tocilizumab: A series of three cases
por: Chochoł-Labun, Joanna, et al.
Publicado: (2021)

Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19
por: Tanner, Tamara, et al.
Publicado: (2020)

IgGs drive COVID-19 myeloid hyperinflammation
por: Park, Matthew D.
Publicado: (2020)

Attenuating hyperinflammation in COVID-19: A change in paradigm?
por: Molnar, Zsolt, et al.
Publicado: (2020)

ACEi reduces hypertension-induced hyperinflammation in COVID-19
por: Lim, Gregory B.
Publicado: (2021)

First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab
por: Zhang, Xuhan, et al.
Publicado: (2020)

Neutrophil Extracellular Traps Contribute to COVID-19 Hyperinflammation and Humoral Autoimmunity
por: Torres-Ruiz, Jiram, et al.
Publicado: (2021)

Hyperinflammation, T cells, and endotoxemia
por: Inoue, Makoto, et al.
Publicado: (2015)

COVID‐19: lambda interferon against viral load and hyperinflammation
por: Andreakos, Evangelos, et al.
Publicado: (2020)

Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?
por: Ritchie, Andrew I, et al.
Publicado: (2020)

Altered Cholesterol and Lipid Synthesis Mediates Hyperinflammation in COVID-19
por: Sohrabi, Yahya, et al.
Publicado: (2021)

The role of ibrutinib in COVID-19 hyperinflammation: A case report
por: Maynard, Suzanne, et al.
Publicado: (2021)

Management of severe hyperinflammation in the COVID-19 era: the role of the rheumatologist
por: Papadopoulou, Charalampia, et al.
Publicado: (2020)

Candidemia in COVID‐19 treated with corticosteroids and tocilizumab
por: Yamamoto, Koichiro, et al.
Publicado: (2021)

Hyper-inflammatory Syndrome in a Child With COVID-19 Treated Successfully With Intravenous Immunoglobulin and Tocilizumab
por: Balasubramanian, S., et al.
Publicado: (2020)

Successful treatment of a critical COVID-19 patient with tocilizumab
por: Tsao, Shih-Ming, et al.
Publicado: (2021)

A brewing storm: The neuropsychological sequelae of hyperinflammation due to COVID-19
por: Cothran, Thomas P., et al.
Publicado: (2020)

COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs
por: TUFAN, Abdurrahman, et al.
Publicado: (2020)

COVID-19 and Neutrophils: The Relationship between Hyperinflammation and Neutrophil Extracellular Traps
por: Borges, Leandro, et al.
Publicado: (2020)

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation
por: Salvatierra, Juan, et al.
Publicado: (2021)

Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation
por: Bonaventura, Aldo, et al.
Publicado: (2022)

Hyperinflammation Reduces Midazolam Metabolism in Critically Ill Adults with COVID-19
por: Smeets, Tim J. L., et al.
Publicado: (2022)

Early experience with anti-interleukin-6 therapy in COVID-19 hyperinflammation
por: Marwah, Vikas, et al.
Publicado: (2021)

Hyperinflammation due to COVID-19 and the Targeted Use of Interleukin-1 Inhibitors
por: Gasparyan, Armen Yuri, et al.
Publicado: (2022)

Refractory Uveitis in Patient with Castleman Disease Successfully Treated with Tocilizumab
por: Oshitari, Toshiyuki, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_24kj7ai30raldi6jkpsmjqglke